Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 4/20 | 0.55 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.47 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.46 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | EDNRB | P24530 | 1/20 | 0.40 |
| ▸ | EDNRA | P25101 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1827704 | 0.83 | KCNN4 (0.53) | KCNN4CES2CES1HDAC3HDAC1 | |
| SCHEMBL22655986 | 0.83 | KCNN4 (0.68) | KCNN4CES2CES1HDAC3HDAC1 | |
| SCHEMBL31691808 | 0.83 | KCNN4 (0.68) | KCNN4CES2CES1HDAC3HDAC1 | |
| SCHEMBL4941607 | 0.83 | KCNN4 (0.53) | KCNN4CES2CES1HDAC3HDAC1 | |
| SCHEMBL9044136 | 0.83 | KCNN4 (0.53) | KCNN4CES2CES1HDAC3HDAC1 | |
| SCHEMBL31560818 | 0.83 | KCNN4 (0.53) | KCNN4CES2CES1HDAC3HDAC1 | |
| SCHEMBL3934832 | 0.83 | KCNN4 (0.53) | KCNN4CES2CES1HDAC3HDAC1 | |
| SCHEMBL9856001 | 0.81 | KCNN4 (0.56) | KCNN4CES2CES1HDAC3HDAC1 | |
| SCHEMBL1626915 | 0.81 | APP (0.55) | APPCES2MAPTKMT2A | |
| SCHEMBL25460782 | 0.80 | KCNN4 (0.50) | KCNN4LTB4RLTB4R2CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340528-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2025-11-06 | — | — | US | disclosed |
| US-12459920-B2 | Targeted protein degradation | MONTE ROSA THERAPEUTICS AG (CH) | 2025-11-04 | — | — | US | disclosed |
| US-20250243180-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2025-07-31 | — | — | US | disclosed |
| WO-2025024521-A1 | SUBSTITUTED PIPERIDINEDIONES FOR TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS, INC. (US) | 2025-01-30 | — | — | WO | disclosed |
| WO-2014186704-A2 | NOVEL COMPOUNDS FOR THE TREATMENT OF CYSTIC FIBROSIS | N30 PHARMACEUTICALS, INC. (US) | 2014-11-20 | — | — | WO | disclosed |
| CN-102083794-A | Urea compounds as gamma secretase modulators | AMGEN INC | 2011-06-01 | — | — | CN | disclosed |
| US-20110118234-A1 | Urea Compounds as Gamma Secretase Modulators | AMGEN INC. | 2011-05-19 | — | — | US | disclosed |
| US-7928139-B2 | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof | AMGEN INC. (US) | 2011-04-19 | — | — | US | disclosed |
| EP-2300427-A1 | UREA COMPOUNDS AS GAMMA SECRETASE MODULATORS | AMGEN INC. (US) | 2011-03-30 | — | — | EP | disclosed |
| US-20100048572-A1 | NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF | AMGEN INC. (US) | 2010-02-25 | — | — | US | disclosed |
| US-7635715-B2 | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof | AMGEN INC. (US) | 2009-12-22 | — | — | US | disclosed |
| WO-2009137404-A1 | UREA COMPOUNDS AS GAMMA SECRETASE MODULATORS | AMGEN INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| EP-2111399-A2 | NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF | Amgen Inc. (US) | 2009-10-28 | — | — | EP | disclosed |
| US-20090093483-A1 | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof | AMGEN INC. (US) | 2009-04-09 | — | — | US | disclosed |
| WO-2008076427-A2 | NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF | AMGEN INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| US-20060128634-A1 | Alpha, alpha-disubstituted benzylglycine derivatives as HIV protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-06-15 | — | — | US | disclosed |
| WO-2004043355-A2 | ALPHA, ALPHA-DISUBSTITUTED BENZYLGLYCINE DERIVATIVES AS HIV PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-05-27 | — | — | WO | disclosed |
| WO-2004043355-A2 | ALPHA, ALPHA-DISUBSTITUTED BENZYLGLYCINE DERIVATIVES AS HIV PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118234-A1 | Urea Compounds as Gamma Secretase Modulators | BACE1, BACE2, PSEN1 | KCNN4 4427/4885APP 8/4885LTB4R 3975/4885 |
| US-20100048572-A1 | NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF | EGLN2, EGLN3, HIF1AN | KCNN4 4743/4885APP 2779/4885LTB4R 4045/4885 |
| US-20090093483-A1 | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof | EGLN2, EGLN3, HIF1AN | KCNN4 4743/4885APP 2779/4885LTB4R 4045/4885 |
| US-20250243180-A1 | TARGETED PROTEIN DEGRADATION | NEK7, NEK1, RIPK1 | KCNN4 4456/4885APP 325/4885LTB4R 2463/4885 |
| US-12459920-B2 | Targeted protein degradation | NEK7, NEK1, RIPK1 | KCNN4 4452/4885APP 323/4885LTB4R 2470/4885 |
| US-20060128634-A1 | Alpha, alpha-disubstituted benzylglycine derivatives as HIV protease inhibitors | PEPD, DNPEP, PREP | KCNN4 4828/4885APP 574/4885LTB4R 3304/4885 |
| US-20250340528-A1 | TARGETED PROTEIN DEGRADATION | NEK7, NEK1, RIPK1 | KCNN4 4456/4885APP 325/4885LTB4R 2463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.